β-Blockers and atrial fibrillation: hypertension and other medical conditions influencing their use

Can J Cardiol. 2014 May;30(5 Suppl):S38-41. doi: 10.1016/j.cjca.2013.09.029. Epub 2013 Oct 9.

Abstract

β-Blockers are among the most frequently used drugs in patients with atrial fibrillation. They are often used for ventricular rate control, acutely in emergency situations and chronically, in patients with persistent or permanent atrial fibrillation. They are also used, with less evidence of benefit, to prevent the first occurrence or recurrence of atrial fibrillation, particularly in patients with hypertension. They are effective in reducing ventricular rate, potentially leading to an improvement in symptoms and well-being. They are particularly indicated in patients with heart failure and atrial fibrillation; the choice of β-blockers in this condition should be guided by tolerability and effects on symptoms and well-being.

Publication types

  • Review

MeSH terms

  • Adrenergic beta-Antagonists / administration & dosage*
  • Atrial Fibrillation / drug therapy*
  • Atrial Fibrillation / etiology
  • Atrial Fibrillation / physiopathology*
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Female
  • Heart Failure / drug therapy
  • Heart Failure / prevention & control
  • Humans
  • Hypertension / complications
  • Hypertension / diagnosis
  • Hypertension / drug therapy*
  • Male
  • Prognosis
  • Risk Assessment
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • Adrenergic beta-Antagonists